The Revenue Miss Has Not Broken Earnings; the Lower Multiple Now Pays for the Risks

Results vs. Consensus

Q4 FY2026: quarter ended March 31, 2026

Year-over-year comparisons

Quarter-over-quarter comparisons

Revenue: A roughly $5–6 billion shortfall is large even for a distributor. The mix matters: oncology revenue grew 35%, while North American Pharmaceutical grew just 3%. Branded-price declines reduced that segment’s growth by approximately three percentage points, and GLP-1 distribution revenue declined 4% sequentially. Those effects explain why sales growth can weaken without a comparable profit loss. They do not establish that the entire consensus miss was anticipated or price-related; no complete dollar bridge to expectations was supplied.

Margins: The standing operating-leverage thesis continues to work, with a different quarterly shape. Adjusted gross margin expanded 28 basis points, while operating margin expanded about 11. Expenses rose almost as fast as gross profit, so the expense-to-gross-profit ratio improved only about 20 basis points, far below Q2’s 570. Acquisitions and technology spending have ended the stretch of declining absolute expenses. Our outlook relies on specialty mix and measured cost efficiency rather than another large expense reset.

EPS: Adjusted earnings grew 12.6%, and fewer shares lifted EPS growth to 15.5%. Repricing current adjusted earnings at the prior-year share count gives approximately $11.39, about $0.30 below reported EPS. Applying the prior-year 13.0% tax rate to current adjusted pretax profit reduces EPS by roughly another $0.12. These are year-over-year sensitivities, not deductions from the consensus beat. Q4’s large sequential EPS increase mainly reflects the tax reversal and seasonal access-services strength, not a 25% sequential improvement in the business.

Fiscal 2026: the full-year test

Full-year adjusted EPS of $39.11 finished inside the final $38.80–$39.20 guidance range and above our Q3 estimate of $38.95 by $0.16. The company’s annual EPS bridge attributes $5.50 of growth to operating performance and $1.23 to share count, offset by $0.57 from McKesson Ventures and $0.10 from other items. That establishes operating progress without treating every dollar of EPS growth as organic. The modest 3.5% cash-flow growth is the more restrained measure of the year’s improvement.

Segment Performance

North American Pharmaceutical: stronger unit economics, uneven margin progression

The largest segment earned $980M on $79.1B of revenue, with a 1.24% margin versus 1.15% a year earlier. Specialty distribution to health systems and operating efficiency supported profit growth despite lower branded sales. That is a useful test of the fee-for-service case behind our initial coverage: lower drug prices need not reduce the compensation for distribution services proportionately.

“Importantly, the impact of branded pricing declines and the sequential decline in GLP-1 volumes had no impact on operating profit in the quarter.”
— Britt Vitalone, CFO

Assessment: Q4 challenges the margin-dilution bear case, but does not complete the clean trend we sought in Q2. Q3 margin contracted two basis points year over year before Q4 expanded nine; FY2026 margin was flat at 1.03%. We retain the operating-leverage pillar and expect 7.5% FY2027 segment profit growth, while allowing for fluctuations in product mix and customer comparisons.

Oncology & Multispecialty: the acquisition headline gives way to the organic test

Adjusted profit rose 53% to $385M, and margin improved 36 basis points to 3.03%. PRISM Vision and Core Ventures still contribute heavily to the comparison. Management reports 13% organic profit growth excluding acquisitions, slowing from Q3’s 15% to the floor of its 13%–16% long-term target. The durability of that base matters more now than the acquisition-enhanced headline.

“Excluding the impact of acquisitions, organic operating profit grew a healthy 13%, reflecting strong underlying performance.”
— Britt Vitalone, CFO

Assessment: The results support our specialty-services pillar, without evidence of a new organic acceleration. The FY2027 profit guide of 13.5%–17.5% is encouraging because it laps the acquisitions and the $51M Q2 gain. It turns the acquisition-anniversary question from our last recap into an explicit delivery test; our 15.5% estimate assumes the provider network keeps growing and integration continues to work.

Prescription Technology Solutions: the profit target survived the spending ramp

RxTS generated $322M of adjusted profit at a 21.54% margin, up 26 basis points year over year and 307 sequentially. Annual patient reverifications make fiscal Q4 seasonally strong. More tellingly, FY2026 profit rose 17% to $1,129M, landing inside Q3’s raised 14%–18% range despite the planned investment increase. That fulfills the Q3 commitment to sustain profit growth through higher technology spending.

“Our fiscal fourth quarter is typically the busiest time of the year as we support patients with their annual verifications. This year, we delivered the most successful season to date, supporting a record number of 3.4 million patients in their journey to access the medicines they need.”
— Brian Tyler, CEO

Assessment: FY2027’s 2.5%–6.5% revenue growth guide initially looks weak beside 11%–15% profit growth. With third-party logistics representing roughly 55% of sales, a slower top line can coexist with a better mix of access and affordability services. We expect 13% profit growth; a slowdown in those services, rather than logistics revenue alone, would challenge the network thesis.

Medical-Surgical: separation progress does not repair the operating trend

Revenue rose only 1% and adjusted profit fell 5% to $271M, following a 10% profit decline in Q3. Lower ambulatory-care contributions and weak vaccine and testing demand outweighed specialty-volume growth. FY2026 profit of $1,029M grew less than 1%, below the low-end 2% growth expectation carried in our Q2 recap.

“During the quarter, illness season product demand, including vaccines and testing, trended below the prior year.”
— Britt Vitalone, CFO

Assessment: FY2027’s flat-to-4% profit guide implies stabilization, not recovery to the growth profile of the retained specialty businesses. Our 2% estimate assigns no benefit from a stronger illness season. The separation can improve the portfolio mix, but its value depends on financing and costs as well as the price a new investor will pay.

Corporate and Other: Corporate expense rose to $209M from $157M, including $15M of McKesson Ventures losses and more technology infrastructure spending. Norway contributed just $8M of adjusted operating profit in its final partial quarter. Its January 30 disposal completes the European exit; the $480M disposal gain is not a recurring source of earnings.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: Management remained confident, as in Q3, and more directly addressed the distinction between drug revenue and service economics. Answers were specific about near-term financing and tax items, but less conclusive about long-term biosimilar reimbursement and the recurring costs left after separation.

1. The first pricing test supports the prior reduction in policy risk

Q3 reduced policy risk to EMERGING because January pricing was already included in higher guidance. Q4 now tests that expectation against realized results: the first Inflation Reduction Act branded-price changes reduced revenue growth, while North American Pharmaceutical profit still grew 11%. Management says the price changes themselves had no Q4 profit impact. This supports contractual and service-based insulation, although it does not establish how later renewals will be priced.

“In the past quarter, we successfully navigated the first wave of branded pharmaceutical price changes related to the Inflation Reduction Act. As expected, there was an impact to revenue growth, but the fundamentals of our business and the strength of our value proposition to manufacturers remain very strong, evidenced by the double-digit adjusted segment operating profit growth in fiscal '26. We continue to manage the business with discipline, ensuring appropriate compensation for the critical services we provide, which position us well for sustained long-term growth.”
— Brian Tyler, CEO

Assessment: Policy risk remains EMERGING. Realized pricing insulation strengthens the expectation behind Q3’s reduction in risk, while the longer-term economics remain unsettled. Biosimilar reimbursement, direct access channels and manufacturer negotiations still constrain the multiple; our valuation stops at 19x rather than assuming policy risk has disappeared.

2. Medical-Surgical now has a transaction framework, with financing attached

Apollo has agreed to invest $1.25B for approximately 13% of Medical-Surgical at a stated $13B enterprise value. April’s $1B term loan, a $1B revolving facility and planned additional term borrowing of up to $2.25B establish an independent capital structure. The revolver is capacity, not another $1B of assumed proceeds. Regulatory approvals and customary closing conditions remain outstanding for the equity transaction.

“The proceeds from all these transactions will be used to satisfy existing intercompany agreements with McKesson Corporation. We intend to deploy these funds in line with our disciplined capital allocation strategy, principally towards share repurchases.”
— Britt Vitalone, CFO

At the consolidated level, borrowing is still debt while McKesson retains control. Interest guidance rises from $230M to $380M–$420M, and adjusted noncontrolling-interest expense rises from $242M to $295M–$325M. At our midpoint assumptions, those increases cost approximately $1.77 per share after the interest tax shield. They are material offsets to a smaller share count, not reasons to ignore the capital release.

Assessment: The agreement gives the separation a market valuation and improves financing readiness. Portfolio reshaping remains AT RISK: the call does not resolve Q3’s distinction between an IPO by the second half of calendar 2027 and the earlier full-exit objective, or quantify recurring stranded costs. The stated $13B enterprise value is not additional value available to common shareholders on top of the earnings already in our target. We continue to value the consolidated business, including Medical-Surgical income, debt service and minority claims; no separate separation premium is added.

3. Redeemable minority interests deepen an existing earnings-quality concern

Q3 moved this risk to EMERGING after $25M of quarterly redemption adjustments and a $802M redeemable-interest balance showed that acquisition growth creates claims beyond ordinary minority earnings. Q4’s $122M noncash Core Ventures remeasurement is larger, and the balance rises to $943M. A noncash valuation adjustment can be appropriate to exclude from current operating performance while still representing an economic cost to the majority owner.

“Second, fourth quarter results included approximately $122 million of noncash adjustments to redeemable noncontrolling interest from the Core Ventures acquisition in our oncology and multispecialty segment.”
— Britt Vitalone, CFO

Assessment: The adjusted-earnings risk remains EMERGING, with stronger evidence of its economic significance. The concern is the gap between segment growth and value retained by common shareholders, not a claim that this quarter’s adjusted EPS was overstated by all exclusions. GAAP EPS actually exceeds adjusted EPS because the Norway and LIFO gains are removed. Future redemptions and ordinary minority earnings need to remain visible alongside acquisition returns.

4. Cash delivery beat the prior concern, but the next year still steps down

Q4 free cash flow of $3.236B exceeded the $2.226B–$2.626B needed in our Q3 assessment to achieve annual guidance. Second-half cash reached $4.293B, and FY2026 finished above the $4.4B–$4.8B range. The expected year-end cash delivery was achieved. Yet FY2027 guidance of $4.5B–$4.9B implies a decline of 9%–17% from FY2026’s $5.410B. At the midpoint, conversion falls from 111% of adjusted earnings to about 91% of our earnings estimate. Some FY2026 working-capital benefit is timing-sensitive rather than a new cash run rate.

“This performance was driven by strong operating results and working capital timing. As a reminder, our free cash flow and working capital metrics can vary quarter-to-quarter, including the day of the week the quarter closes.”
— Britt Vitalone, CFO

Assessment: The cash result supports the operating franchise and limits the old downside concern. The FY2027 guide still matters because $5B of planned repurchases plus dividends exceeds guided free cash flow before acquisitions. Separation financing supports the gap; recurring cash conversion, not announced authorization, determines how readily that pace can continue.

5. Automation is producing evidence, with a slower incremental margin payoff

The new Montreal distribution center expands capacity with automated storage and retrieval, while AI-enabled inventory planning connects demand, supply and operations. In biopharma services, each employee supported 120 more patients during reverification season. These are tangible operating measures, although neither establishes an isolated enterprise AI return on investment.

“We implemented an advanced planning system that uses AI to connect and orchestrate end-to-end planning across demand, supply, inventory and operations inside an integrated environment. This transformation enables us to deliver working capital savings and meaningfully contributed to the strong operating cash flow in fiscal 2026.”
— Brian Tyler, CEO

Assessment: The annual 293-basis-point reduction in expense relative to gross profit supports the fixed-cost leverage pillar. Q4’s much smaller improvement warns against annualizing the Q2 pace. We allow corporate expense to fall to $610M from $654M in line with guidance, while continued technology investment absorbs part of the operating gains.

6. A broader oncology network increases the value of each practice addition

The network added more than 570 providers in FY2026, and Ontada is incorporating in-office dispensing data from Florida Cancer Specialists. That expands what McKesson can offer biopharma customers beyond physical distribution: information about therapy adoption, practice workflows and potential clinical-trial recruitment. Ambient Scribe may also make the network more attractive to physicians by reducing administrative work.

“Ontada, our data and insights business, for example, is now incorporating in-office dispensing data from Florida Cancer Specialists and Research Institute. This expands the data we provide to biopharma customers to better assess adoption and performance trends across the broader community oncology landscape.”
— Brian Tyler, CEO

Assessment: The network-and-services mechanism remains the strongest reason to accept mid-teens oncology profit growth after the acquisitions lap. We assign no distinct revenue line to new AI or data products; their contribution must appear in the existing segment’s organic growth and return on acquired capital.

7. Leadership transition raises the importance of financial continuity

This was Britt Vitalone’s final earnings call as CFO; he will remain an adviser during the transition and separation. Brian Tyler became board chair effective May 1, alongside Dominic Caruso as lead independent director. The business is simultaneously changing its financing structure and preparing a carve-out, so consistency in cash-flow, noncontrolling-interest and adjusted-earnings disclosure matters more than a routine succession announcement.

“As planned, Britt will continue to support the team through the CFO transition, ensuring continuity and stability for the team and operations.”
— Brian Tyler, CEO

Assessment: Advisory continuity reduces transition risk, but the next finance leadership team inherits a more complicated ownership structure. We leave conviction at 6 rather than increasing it on the valuation upgrade; delivery against the initial FY2027 bridge will be the first useful test.

Guidance & Outlook

The FY2026 exit and initial FY2027 outlook

The $44.20 EPS midpoint is 13.0% above FY2026, near the bottom of the 13%–16% long-term algorithm. On the company’s comparable $38.37 baseline, excluding Norway earnings and the US Oncology Network gains, the range represents approximately 14%–16% growth. That resolves the apparent conflict with our prior concern about guidance below the long-term target: the disclosed comparison changes, rather than a new reduction in the operating ambition, explain much of the gap.

“We expect the earnings per share cadence to be broadly similar to fiscal 2026 from a first-half, second-half perspective with quarter-to-quarter variability in part driven by the timing of discrete tax items recognized in fiscal 2026.”
— Britt Vitalone, CFO

Implied cadence: Using the FY2026 split as a planning approximation gives about $20.5 of first-half and $23.7 of second-half EPS at our $44.20 full-year estimate. These are our allocations, not quarterly guidance. Q2’s tax benefit and Q4’s 12.1% rate create demanding comparisons; a slower individual quarter would not on its own establish weakening demand.

Expectations and guidance style: The first FY2027 range of $43.80–$44.60 brackets our Q3 estimate of $43.80 and supports a $0.40 increase to the new midpoint. FY2026’s repeated guidance increases justify some confidence in the starting range, but the year finished within the final band rather than above its ceiling. Our base case therefore uses the new midpoint and gives no credit for a future raise.

Analyst Q&A Highlights

Does slower RxTS revenue imply a weaker access business?

The opening challenge separated logistics revenue from technology demand and asked whether the GLP-1 distribution slowdown was reaching prior authorizations. Management’s response identifies a credible mix explanation, while stopping short of a distinct access-volume forecast.

Q: “On the RxTS segment, looking at the fiscal '27 revenue growth here, 2.5% to 6.5%. I think maybe that's a little bit slower than where growth has been over the past few years, but there's a lot of different pieces of that segment. Is the slower growth coming from the 3PL business? Or is it coming from another part of the business? And as we think about the GLP-1 component in the prior authorization business, you mentioned that GLP-1 revenue declined 4% quarter-over-quarter in the distribution business. What are your expectations for GLP-1 growth within that prior authorization business over the course of fiscal '27?”
— Allen Lutz, Bank of America

A: “If you think about the composition of revenue in that segment, as we've talked about over the last several years, the 3PL component of that business represents roughly 55% of total revenue. And as we've talked about, that business can vary quite significantly from quarter-to-quarter or year-to-year, driven by a number of factors. It could be the timing of product launches or products that we may support under those 3PL programs. It could be the timing of program launches for products that are launching. All of those things can drive some significant variability for the revenue portion of that 3PL business. And as I mentioned, it's really the predominant component of revenue for that segment. When you look at the operating profit momentum, which our guide for next year is really at the upper end of the long-term target range. That's really reflective of the really good recognition and support and demand that we're getting for the programs of our technology services, primarily our access programs, which include GLP-1s. So I think that's a good signal that our programs within our technology services aspect continue to have strong demand and are driving a lot of value.”
— Britt Vitalone, CFO

Assessment: Profit guidance is a better signal than logistics-heavy revenue here, and the FY2026 investment test was passed. It remains guidance rather than a measured FY2027 access-demand result. We raise our FY2027 profit-growth estimate to 13% from 11.5%, with access volumes and margins carrying more weight than total segment revenue.

What remains when the oncology acquisitions lap?

The question pressed for the organic and acquired components of next year’s growth. Management pointed to the existing organic rate and the prior gain; elsewhere in the same exchange it said January weather disruption recovered within the quarter. Weather therefore does not explain a weaker annual comparison.

Q: “Just really want to dig into oncology and multispecialty on the guidance side. Can you talk about what's in revenue and adjusted operating profit as far as organic versus inorganic, where we are as far as some of the acquisitions that you made and how they'll contribute to 2027?”
— Lisa Gill, JPMorgan

A: “As we think about the oncology and multispecialty segment, we are going to be lapping both acquisitions of PRISM and Core Ventures that we completed in the first quarter of last year. And underlying -- I mentioned this a couple of times in my script, the organic growth of that segment has really been coming in right around 13%. Now when you look at the guide, remember, as I called out a couple of times here, last year, we did have $51 million in gains in the second quarter related to sale of an equity investment and other market actions. So the organic performance of the segment is actually a little bit stronger than the guide reads. And we believe that the guide is strong, and it's actually at the upper end of the long-term target range. So we feel good that the acquisitions are performing well. The integrations are going well. And as we lap that, the organic growth rate is going to be really in the middle of that long-term target range.”
— Britt Vitalone, CFO

Assessment: The answer directly addresses the anniversary risk identified in Q2 and supports a mid-teens forecast. It does not provide a complete dollar bridge between new practices, acquired growth and same-practice activity, so we treat 15.5% as an achievable target with execution risk, not as already demonstrated organic growth.

Can biosimilars help distribution while squeezing physician reimbursement?

The pointed challenge was whether lower drug prices improve practice economics when reimbursement follows average selling price. The answer acknowledged the distinction between distribution and community oncology, then explained why coordinated adoption gives McKesson bargaining value.

Q: “And so when you think about the price of those oncology drugs coming down, Britt, if I heard you correctly, you just said it's a win-win-win for the provider. But if he's getting reimbursed based off of ASP and the price of that drug is sort of coming down, is the practice better off?”
— Glen Santangelo, Barclays

A: “The dynamic is a little more complicated in the community setting, the Part B setting. We've got this dynamic of ASP. And usually when -- in our early experience with these products, when they launch, the initial launch, this is a good thing for the practice, as Britt referenced. And then you've got to make sure you sustain that ASP. And we've seen biosimilars come into the market and come out of the market. But the one advantage that we have is because of the network effects, particularly in U.S. oncology and we think ultimately in retinology, is we can drive adoption to these biosimilars or to the innovator drug in a more uniform and rapid way. And that creates value for the manufacturer that they're willing to compensate the GPO and the distribution business for.”
— Brian Tyler, CEO

Assessment: This is a useful mechanism, with an explicit reimbursement qualification. Network coordination can earn manufacturer compensation, but the response does not size the net margin outcome after ASP erosion at practices. That unresolved trade-off is why policy risk remains EMERGING even after the benign Q4 distribution result.

Why is free cash flow falling when operating profit is rising?

The question tested why cash conversion would fall despite profit growth. Management attributed part of the strong Q4 cash result to working-capital timing.

Q: “I wanted to focus a bit on free cash flow and capital deployment priorities for fiscal '27. Guidance does imply a bit of a step down in free cash flow, about 13% reduction year-over-year despite the 10% increase in AOP. So I was just curious what's driving that reduction in conversion in fiscal '27.”
— Daniel Grosslight, Citi

A: “I mentioned in my remarks for '26 that part of our cash flow generation in the fourth quarter was driven by timing. And we've always talked about timing, whether it's the day of the week that the quarter ends on or the day of the week that we either have a large payment to a manufacturer. It could be a Tuesday, Wednesday thing at the end of the quarter. Working capital timing does impact quarter-to-quarter. But if you look over a long period of time, the moving average on cash flow is up, and it's in line with really the performance that we've had on an operational basis.”
— Britt Vitalone, CFO

Assessment: Timing is a plausible explanation for the lower guide, but it is not a quantified cash bridge. The $4.7B midpoint remains our forecast. Acquisition flexibility also means $5B of repurchases is a capital-allocation plan, not an unconditional commitment independent of opportunities or credit quality.

Why does pharmaceutical revenue slow while profit guidance stays firm?

The final question tested whether lower revenue growth reflects pricing or lost operating momentum. Management named three comparisons: a large customer onboarded earlier, Rite Aid revenue disappearing, and a full year of branded-price changes.

Q: “If I can go back basically to the North America Pharma guide. Obviously, you kind of touched on the rev guide here, and I would understand that's probably sort of the continued impact of price changes in the market. First, is that the right way to think about it? But the second part is, when you look at the AOI growth here, it's actually a little bit above the LRP targets of 5% to 8%. Maybe you could help us a little understand what's maybe driving the better-than-expected performance there?”
— Charles Rhyee, TD Cowen

A: “As we think about going from '26 to '27, there's a couple of things that we're lapping here. First of all, we had 1 quarter of revenue related to a large customer that we onboarded in the previous year. So we're lapping that. We also had 3 quarters of revenue related to Rite Aid. It's not an income impact or was a very minor income impact. But from a revenue perspective, we do have 3 quarters of that Rite Aid revenue that we're lapping. And as we mentioned in my remarks, at least in the fourth quarter, we saw some impact from branded pricing manufacturer declines in those prices that we'll have those for a full year now. And so when you look at those factors and you look at the underlying organic growth -- revenue growth of the business, it's actually quite strong when you look at it historically. In terms of the adjusted operating profit growth, we feel really well positioned. As I mentioned, specialty pharmaceuticals continue to grow very well. We're very well positioned and have a scaled position in that marketplace. We're getting great operating efficiency. I talked about the consolidated operating efficiency in terms of operating expenses as a percentage of gross profit was down 293 basis points in FY '26. A lot of that efficiency is coming from the investments that we've made across our network, investments that we made in infrastructure. And certainly, a lot of that is having a positive impact on the North American segment. So again, I think the segment remains strong. There's good momentum in that segment, and we feel good about our '27 guide.”
— Britt Vitalone, CFO

Assessment: The low-profit Rite Aid comparison and drug-price changes reduce the economic weight of the revenue slowdown. Specialty demand and efficiency were also cited in the response as profit drivers. We accept the 7.5% profit midpoint, while watching for any change from price-only pressure to reduced service compensation.

What They’re NOT Saying

1. Recurring stranded costs after Medical-Surgical separation. Audited carve-out statements and transition agreements improve readiness, but the release and call do not supply a net recurring cost number. Q3’s IPO-by-2H-calendar-2027 milestone did not clearly reaffirm the earlier full-exit objective; this call supplies no final IPO date or reconciliation of those endpoints.
2. A separate profit bridge for GLP-1 access and distribution. Category revenue and the Q4 no-profit-impact assertion are helpful. They do not show how fees, access services and cash-pay migration interact across different manufacturer contracts.
3. The long-run net effect of biosimilar ASP erosion. Faster adoption creates value, but manufacturer compensation and practice reimbursement can move differently. A network advantage alone cannot establish the consolidated profit sensitivity.
4. A quantified cash-flow normalization bridge. Working-capital timing explains possible volatility; it does not allocate the $710M midpoint decline in FY2027 free cash flow between reversals, reinvestment and other items.
5. Expected cash timing for redeemable minority interests. A $122M remeasurement is an economic signal even though it is noncash this quarter. The earnings discussion does not size eventual payments or explain the timing well enough to equate adjusted acquisition accretion with cash returns.

Market Reaction

• Pre-print: MCK closed May 7 at $754.76, down 8.0% year to date and 11.9% over 30 days, but up 4.5% over twelve months. The prior 52-week closing range was $659.01–$995.69; the S&P 500 had gained 7.2% year to date.
• May 8 reaction session: The stock opened at $739.75, a 2.0% gap down, traded between $726.02 and $772.42, and closed at $736.09, down $18.67 or 2.5%.
• Participation and relative performance: Volume was 2.2M shares versus a 0.8M 30-day average, 2.6 times normal. The S&P 500 rose 0.8%, leaving MCK about 3.3 percentage points behind.

The negative reaction arrived after a substantial pre-print decline, rather than after the premium valuation behind our Q3 Underperform rating. The intraday recovery above the prior close did not hold. A large revenue miss and a cash-flow guide below the prior year offer plausible reasons for continued caution; the trading data cannot isolate their individual contribution.

We give more weight to the profit guide than to the revenue surprise. Contemporary reactions focus on the same tension, with some price targets rising and others falling despite positive ratings. The evidence supports a debate about earnings durability and valuation, not a consensus conclusion that the business has broken. At the closing price, our upgrade requires only a partial valuation recovery alongside the guided earnings, rather than a return to the prior high.

Street Perspective

Debate: a revenue reset or the beginning of an earnings problem?

Bull view: Specialty profit and distribution margins demonstrate that service economics can survive lower drug prices. The revenue denominator overstates the impact of the first pricing wave.

Bear view: The miss is large, GLP-1 revenue fell sequentially and FY2027 sales growth slows. More manufacturer price pressure could eventually reach contract compensation, even if it did not in Q4.

Our take: The bulls have the stronger near-term operating evidence. We model growth near the segment guide midpoints and keep the bear case tied to flat pharmaceutical profit, rather than treating every lost sales dollar as a lost fee dollar.

Debate: specialty compounding or acquisition arithmetic?

Bull view: Oncology provider additions and RxTS access demand extend growth beyond the deals, with FY2027 segment profit ranges near or above their long-term targets.

Bear view: Oncology’s 53% reported growth falls sharply after the acquisitions lap. Redeemable minority claims and integration expenses reduce what common shareholders keep.

Our take: Thirteen percent organic oncology growth and the fulfilled RxTS profit commitment validate the platform, but support mid-teens expectations rather than extrapolation of the acquisition headline. Our model includes both minority expense and higher interest, and the valuation has no separate AI premium.

Debate: separation creates value or merely brings repurchases forward?

Bull view: An outside equity investment and independent financing validate the carve-out and accelerate capital returns while McKesson retains control.

Bear view: The medical business is barely growing, recurring separation costs remain open, and debt-funded repurchases exchange future flexibility for near-term EPS.

Our take: Capital release is useful at 16.7x FY2027 earnings, but the equity value belongs to the entire financed structure. A $400M interest line and $310M minority-interest line are integral to our estimate. We support the shares on consolidated returns without adding the transaction’s enterprise value a second time.

Our Estimates & Valuation Framework

FY2027 earnings bridge

The bridge produces $44.19 before rounding to our $44.20 estimate. Holding the share count at FY2026’s 124.1M would produce about $41.66, so the projected share reduction contributes roughly $2.53 per share. That is about half the increase from $39.11, illustrating why capital allocation matters as much as the operating outlook. Higher interest and minority expense are already deducted; the buyback contribution is not free accretion.

Change from Q3: Our FY2027 operating-profit forecast rises modestly to $7.084B from $7.047B, with stronger oncology and RxTS assumptions and lower corporate expense offsetting a lower core-pharma estimate. Interest increases $190M and minority expense $40M; the tax assumption falls from 18.5% to 18%, and shares from 121M to 117M. Together these revisions lift the unrounded EPS calculation from $43.82 to $44.19, expressed as a $0.40 increase in our published estimate. The smaller share base offsets the heavier financing burden; it does not establish faster underlying profit growth.

Twelve-month return cases, anchored to the May 8 close of $736.09

Base case: Our approximately $840 value applies 19x FY2027 EPS, down from Q3’s 21x on the same earnings year. We lower the target from Q3’s $919.80 to $839.80 despite raising EPS $0.40. At the prior 21x multiple, the earnings revision adds $8.40; reducing the multiple to 19x subtracts $88.40, a net $80.00 decline. The lower multiple reflects newly specified financing costs and cash normalization: our interest assumption rises to $400M from $210M, minority expense to $310M from $270M, and FY2027 free cash flow is guided below the completed year despite profit growth. These costs are deducted in EPS; the valuation discount also reflects reduced financial flexibility and uncertainty over recurring separation costs. Specialty growth and demonstrated pricing insulation support a premium to the current 16.7x price multiple, but no longer justify the prior 21x assumption.

The modest estimate increase does not drive the upgrade. Since Q3, the reaction-session price has fallen 23.1%, from $957.80 to $736.09, more than the 8.7% decline in our target. That restores prospective return even under the more conservative valuation. At the unchanged 16.7x multiple, earnings delivery alone would not generate our full target return: recovery to 19x is necessary. The catalyst is verification that FY2027 profit and buybacks withstand lower revenue growth as the acquisitions lap. Our 12-month valuation uses FY2027 earnings, the year ending March 2027, without capitalizing an additional year of forecast growth.

Downside and upside: The bear case assumes flat North American Pharmaceutical profit, 10% oncology growth, 8% RxTS growth and a 5% medical decline, with $640M corporate expense, $420M interest, a 19% tax rate, $325M minority expense and 118M shares. That gives approximately $40 EPS; a 16x multiple produces $640. The bull case uses $46 EPS, below the approximately $46.65 obtained by combining favorable ends of the disclosed guidance assumptions, and a 21x multiple. Both are sensitivities rather than company guidance.

Rating support: The $3.28 dividend assumption holds the current $0.82 quarterly rate flat. Base total return of 14.5% exceeds our assumed 8% S&P 500 return over the same 12 months by about 6.5 percentage points, with approximately 13% downside in the modeled bear case. That supports Outperform at moderate conviction. A $100M recurring pretax cost missed in the bridge would reduce EPS by about $0.70 and value at 19x by roughly $13; separation costs and fee pressure remain meaningful even at the lower multiple.

Thesis Scorecard Post-Earnings

Prior commitments: Q4 EPS of $11.69 landed inside the $11.34–$11.74 needed in Q3 to achieve annual guidance, while the 12.1% tax rate was below our roughly 14.8% estimate. Core profit of $980M met the prior $925M–$1,050M implied range and margin expansion resumed. RxTS delivered inside its raised 14%–18% profit range; $3.236B of Q4 free cash flow exceeded the prior requirement. Medical-Surgical’s 5% profit decline missed the approximately flat Q4 needed for its low-end annual outlook. Formal FY2027 guidance now supports a modest EPS raise, but acquisition anniversaries, the separation endpoint and recurring ownership costs remain open.

What changes our view: Delivery of the 5.5%–9.5% pharmaceutical profit range and 13.5%–17.5% oncology range as the acquisitions lap would support the target multiple. We also want recurring separation costs, the next financing milestones and free cash flow inside $4.5B–$4.9B. Sustained fee pressure producing flat pharmaceutical profit, organic oncology growth below the 13% long-term floor, or recurring costs that materially reduce the $44.20 bridge would move the case toward our downside. A clear net-benefit separation case and stronger cash conversion would raise conviction.

Overall: The operating thesis is stronger than the sales headline, with better evidence on pricing insulation and a fulfilled RxTS commitment. Cash conversion and minority claims keep the financial-quality risks live. The largest change is that the 23.1% price decline since Q3 exceeds our target reduction, restoring an attractive return despite a lower justified multiple.

Action: Upgrade to Outperform from Underperform, conviction 6. We expect McKesson to outperform the S&P 500 over the next twelve months on guided earnings and a partial valuation recovery. The case is supported by specialty service economics and a lower starting multiple, with explicit allowances for financing costs, normalizing cash flow and the unfinished separation.